New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients

Early Biomarkers of Acute Kidney Injury in Liver Transplant Patients

The purpose of this study is to find new blood and urine tests that detect acute kidney injury earlier than our current blood tests in patients receiving a liver transplant.

Patients with end stage liver disease that receive a liver transplant will be studied to determine if novel serum and urine biomarkers (serum cystatin C, urine interleukin-18 [IL-18] and urine neutrophil gelatinase associated lipocalin [NGAL]) can predict the outcome measures listed above.

Inclusion Criteria:

• First time liver transplant recipient
• Cadaveric or living donor livers

Exclusion Criteria:

• Unconscious patients or patients who cannot give consent
• Pregnant women
• Prisoners
• Patients receiving dialysis before or during liver transplant operation
• Patients receiving simultaneous liver-kidney transplants